Rosuvastatin dosage
Pro Research Analysisby 
Searched over 200M research papers for "rosuvastatin dosage"
Rosuvastatin Dosage Range and Potency
Rosuvastatin is typically prescribed in doses ranging from 5 mg to 40 mg once daily, with 40 mg being the maximum approved daily dose for most adults 1310. The drug is known for its high potency in lowering low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). For example, a 5 mg dose of rosuvastatin reduces LDL-C by about 39%, while 10 mg achieves a 44% reduction, 20 mg achieves 50%, and 40 mg achieves 55% 13. These reductions are greater than those achieved by equivalent doses of other statins, such as atorvastatin and simvastatin, with rosuvastatin being about three times more potent than atorvastatin for LDL-C lowering 13.
Dose-Response and Pharmacokinetics
The cholesterol-lowering effect of rosuvastatin is linearly related to the dose, meaning that as the dose increases, the reduction in cholesterol is proportionally greater 23. Pharmacokinetic studies show that rosuvastatin reaches its maximum plasma concentration about 5 hours after dosing, and its systemic exposure increases proportionally with doses from 10 mg to 80 mg 210. The drug is generally well tolerated across this dose range in healthy adults 210.
Clinical Efficacy and Safety at Different Doses
Both low (5 mg) and high (20–40 mg) doses of rosuvastatin are effective in improving cardiovascular risk factors, such as arterial stiffness and central hemodynamics, with higher doses providing greater benefits in some parameters, including liver steatosis in patients with non-alcoholic fatty liver disease . In patients with acute myocardial infarction and new-onset atrial fibrillation, both 10 mg and 20 mg doses significantly reduced cholesterol and improved heart function, with no significant difference in adverse clinical events between the two doses over 12 months . In metabolic syndrome, rosuvastatin dose-dependently lowers not only cholesterol but also other lipid classes, such as sphingolipids and phospholipids .
Special Considerations: Chronic Kidney Disease
For patients with chronic kidney disease (CKD), especially those with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m², lower doses of rosuvastatin are recommended due to limited data on safety at higher doses in this population. However, studies show that nearly half of CKD patients with low eGFR are prescribed higher-than-recommended doses, highlighting the need for careful dose adjustment in renal impairment .
Comparative Effectiveness and Tolerability
High-dose rosuvastatin (40 mg) is as effective as high-dose atorvastatin (80 mg) in post-percutaneous coronary intervention (PCI) patients for lowering LDL-C, but atorvastatin may be better tolerated and more cost-effective in some settings 138. Adverse effects and tolerability profiles are generally similar between rosuvastatin and placebo in short-term studies, but some data suggest higher rates of gastrointestinal side effects with high-dose rosuvastatin compared to atorvastatin .
Conclusion
Rosuvastatin is a highly potent statin with a dose range of 5–40 mg daily, providing strong, dose-dependent reductions in LDL-C and other atherogenic lipids. The choice of dose should be individualized based on the patient’s cardiovascular risk, comorbidities, and kidney function. Lower doses are recommended for patients with significant renal impairment. Both efficacy and safety are generally favorable across the approved dose range, but careful monitoring is advised, especially at higher doses and in special populations.
Sources and full results
Most relevant research papers on this topic